Hims & Hers Health posted its fastest top-line growth in more than a year, but the quarter's profitability fell short. The company reported earnings of $0.03 per share, well below the $0.07 consensus and the $0.09 Earnings Whisper number, a 66.7% shortfall. Earnings fell 50.0% from a year ago. Revenue of $890.37 million rose 48.6% but was 0.3% below the $893.37 million consensus. The central tension is that growth accelerated for a second straight quarter, from 4% in Q1 to roughly 40% in Q2 to 49% now, while nearly every profitability and engagement measure moved the other way. Management cut full-year Adjusted EBITDA guidance for the third time and reported the company's first sequential subscriber decline.

The quality of the quarter deserves scrutiny. On a GAAP basis, Hims & Hers lost $33.0 million, or $0.14 per share, compared with net income of $15.8 million a year earlier. The adjusted figure excludes $35.4 million of acquisition and earn-out costs and $3.8 million of restructuring charges. Gross margin fell to 57% from 74% a year ago and from about 64% adjusted in Q2. The decline reflects a mix shift toward branded weight-loss medications, which carry lower margins, and toward international revenue. Adjusted EBITDA of $82.4 million landed near the middle of the $75-95 million guide, but the margin slipped to 9% from 13%. Much of the revenue acceleration was bought rather than built. International revenue jumped 321% to $233 million, but roughly $135 million of that came from the Eucalyptus acquisition. Excluding Eucalyptus, international growth was about 80%, which is strong but less spectacular than the headline. Domestic growth did improve to 21% from 16%.

The call made clear that management is deliberately trading subscribers for positioning. Subscribers fell about 100,000 sequentially to roughly 2.8 million, after adding about 300,000 in Q2. Management guided for another quarter of subscriber headwinds as it slows U.S. weight-loss marketing ahead of a reset of its weight-loss product lineup in early 2027. Revenue per subscriber rose to $105 a month from $81, so the remaining base is spending far more. Expense discipline also showed:

• Marketing fell to 28% of revenue, from 34% in Q2 and 36% in Q1.
• Free cash flow swung to a positive $26 million from negative $68 million in Q2.

The cash improvement needs context, however. Receivables rose by about $396 million this year and payables by about $372 million, partly offsetting each other in working capital. The balance sheet now also carries $479 million of acquisition payments due within a year and $1.37 billion of convertible notes. The tone shifted noticeably. Q2's message of "playing offense" became talk of "near-term volatility."

Guidance is where bears have legitimate ammunition. Full-year Adjusted EBITDA guidance now stands at $257-277 million. That is down from $275-325 million last quarter, $275-350 million in Q1 and $300-375 million when the year began. Management attributed the latest cut to aggressive pricing and marketing in the UK and Germany and at least $20 million of deferred weight-loss membership revenue. Full-year revenue guidance narrowed to $3.13-3.15 billion from $3.1-3.3 billion, lowering the midpoint by about $60 million. Fourth-quarter guidance calls for revenue of $875-895 million, roughly flat sequentially, and an EBITDA margin near 9%. Last quarter's outlook had implied about 12% for Q4. International guidance was raised to at least $650 million, and management expects the international business to exceed a $1 billion annual run rate in 2027.

The catalyst list is long, and it is why the story is not broken. Hims & Hers now has an agreement with Eli Lilly to offer access to Zepbound and Foundayo, and it plans to add Novo's CagriSema once available. It launched testosterone replacement therapy, its first controlled substances, and will launch Peptides Plus in late November. Andrew Huberman joined the board, and multi-month weight-loss subscriptions arrive ahead of January. Offsetting risks include:

• ongoing FTC litigation;
• regulatory uncertainty around compounded peptides;
• continued GAAP losses;
• the possibility that subscriber churn persists longer than planned.

The market had already priced in much of the disappointment. Shares closed at $26.00 before the report, down 12.5% from the $29.71 open after the August release. They sat 3.4% below the 200-day moving average and 24.5% below the August 21 high of $34.46. The stock had touched a quarter low of $22.88 on November 5 and recovered about 14% into the print. Investor sentiment remained negative but improved slightly, to -0.28 from -0.32, a modest change. The Earnings Whispers trend readings are mixed: sequential growth and momentum are positive, while price and AVWAP trends remain negative.

The bottom line is that Hims & Hers delivered accelerating revenue alongside deteriorating earnings quality. It missed on EPS, cut profit guidance for a third straight quarter and lost subscribers by design. The Lilly and Novo partnerships and the international expansion give the company a credible 2027 growth story. Until margins stabilize and subscriber counts turn back up, however, investors are being asked to look past near-term results based mostly on management's assurances.